Evidence map›Paper›PMID 30428832›Full record

ArticleBMC geriatrics2018

Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions.

Nawele Boublay, Denis Fédérico, Alain Pesce, Marc Verny, Frédéric Blanc, Marc Paccalin, Thomas Desmidt, Pierre Grosmaître, Olivier Moreaud, Solveig Relland and 3 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC geriatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02052947 (Co-LEsions in Alzheimer Disease and Related Disorders), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02052947 naunknown statusnot on this map

Co-LEsions in Alzheimer Disease and Related Disorders

TypeinterventionalSponsorHospices Civils de LyonRan2014 to 2020Enrolled214ConditionsAlzheimer's Disease, Cerebrovascular Disease, Lewy Body DiseaseArmsSPECT-DaTscan
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Nawele BoublayClinical and Research Memory Centre of Lyon, Hospital of Charpennes, Hospices Civils de Lyon, Lyon, France. nawele.boublay@chu-lyon.fr.ORCID 0000-0002-2074-0298
Denis FédéricoClinical and Research Memory Centre of Lyon, Hospital of Charpennes, Hospices Civils de Lyon, Lyon, France.
Alain PesceDépartement de gérontologie clinique et centre mémoire, Centre Rainier III, Monaco, France.
Marc VernyClinical and Research Memory Centre and Geriatrics department of Ile de France Sud, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
Frédéric BlancGeriatrics day hospital. Geriatrics department, Memory Resources and Research Centre (CMRR), University Hospital of Strasbourg, Strasbourg, France.
Marc PaccalinClinical and Research Memory Centre of Poitiers, CHU Poitiers, Poitiers, France.
Thomas DesmidtClinical and Research Memory Centre of Tours, CHRU Tours, Tours, France.
Pierre GrosmaîtreClinical and Research Memory Centre of Lyon, Hospital of Dugoujon, Hospices Civils de Lyon, Lyon, France.
Olivier MoreaudClinical and Research Memory Centre of Grenoble Arc Alpin, Pôle de psychiatrie et neurologie, CHU de Grenoble, Laboratoire de psychologie et neurocognition, CNRS UMR 5105, Grenoble, France.
Solveig RellandClinical and Research Memory Centre of Lyon, Hospital of Charpennes, Hospices Civils de Lyon, Lyon, France.
Estelle BravantHospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, F-69424, Lyon, France.
Romain BouetINSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Brain Dynamics and Cognition Team, F-69000, Lyon, France.
Pierre Krolak-SalmonClinical and Research Memory Centre of Lyon, Hospital of Charpennes, Hospices Civils de Lyon, Lyon, France.
Centre National de la Recherche Scientifique · FRHospices Civils de Lyon · FRUniversité Claude Bernard Lyon 1 · FRCentre Hospitalier Universitaire de Tours · FRInserm · FRScientific Centre of Monaco · MC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the crucial challenges for the future of therapeutic approaches to Alzheimer's disease (AD) is to target the main pathological processes responsible for disability and dependency. However, a progressive cognitive impairment occurring after the age of 70, the main population affected by dementia, is often related to mixed lesions of neurodegenerative and vascular origins. Whereas young patients are mostly affected by pure lesions, ageing favours the occurrence of co-lesions of AD, cerebrovascular disease (CVD) and Lewy body dementia (LBD). Most of clinical studies report on functional and clinical disabilities in patients with presumed pure pathologies. But, the weight of co-morbid processes involved in the transition from an independent functional status to disability in the elderly with co-lesions still remains to be elucidated. Neuropathological examination often performed at late stages cannot answer this question at mild or moderate stages of cognitive disorders. Brain MRI, Single Photon Emission Computed Tomography (SPECT) with DaTscan®, amyloid Positron Emission Tomography (PET) and CerebroSpinal Fluid (CSF) AD biomarkers routinely help in performing the diagnosis of underlying lesions. The combination of these measures seems to be of incremental value for the diagnosis of mixed profiles of AD, CVD and LBD. The aim is to determine the clinical, neuropsychological, neuroradiological and biological features the most predictive of cognitive, behavioral and functional impairment at 2 years in patients with co-existing lesions.

methodsA multicentre and prospective cohort study with clinical, neuro-imaging and biological markers assessment will recruit 214 patients over 70 years old with a cognitive disorder of AD, cerebrovascular and Lewy body type or with coexisting lesions of two or three of these pathologies and fulfilling the diagnostic criteria for dementia at a mild to moderate stage. Patients will be followed every 6 months (clinical, neuropsychological and imaging examination and collection of cognitive, behavioural and functional impairment) for 24 months. DISCUSSION: This study aims at identifying the best combination of markers (clinical, neuropsychological, MRI, SPECT-DaTscan®, PET and CSF) to predict disability progression in elderly patients presenting coexisting patterns.

trial registrationNCT02052947 .

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBiomarkersCerebrovascular DisordersCognition DisordersCognitive DysfunctionDisease ProgressionFemaleHumansLewy Body DiseaseMagnetic Resonance ImagingMalePredictive Value of TestsProspective StudiesTomography, Emission-Computed, Single-PhotonBiomarkersAlzheimer’s diseaseCerebrovascular diseaseCo-lesionsImagingLewy body dementiaPredictive markers

Identifiers

PMID30428832
PMCPMC6236893
OpenAlexW2901041452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.